- Home
- NCA vs YMAB Comparison
NCA vs YMAB Comparison
Compare NCA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- YMAB
- Stock Information
- Founded
- NCA 1987
- YMAB 2015
- Country
- NCA United States
- YMAB United States
- Employees
- NCA N/A
- YMAB N/A
- Industry
- NCA Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NCA Finance
- YMAB Health Care
- Exchange
- NCA Nasdaq
- YMAB Nasdaq
- Market Cap
- NCA N/A
- YMAB 218.4M
- IPO Year
- NCA N/A
- YMAB 2018
- Fundamental
- Price
- NCA $8.64
- YMAB $4.04
- Analyst Decision
- NCA
- YMAB Buy
- Analyst Count
- NCA 0
- YMAB 11
- Target Price
- NCA N/A
- YMAB $18.73
- AVG Volume (30 Days)
- NCA 59.6K
- YMAB 204.4K
- Earning Date
- NCA 01-01-0001
- YMAB 05-13-2025
- Dividend Yield
- NCA 3.92%
- YMAB N/A
- EPS Growth
- NCA N/A
- YMAB N/A
- EPS
- NCA N/A
- YMAB N/A
- Revenue
- NCA N/A
- YMAB $87,685,000.00
- Revenue This Year
- NCA N/A
- YMAB N/A
- Revenue Next Year
- NCA N/A
- YMAB $18.83
- P/E Ratio
- NCA N/A
- YMAB N/A
- Revenue Growth
- NCA N/A
- YMAB 3.38
- 52 Week Low
- NCA $7.77
- YMAB $3.84
- 52 Week High
- NCA $9.12
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- NCA 62.72
- YMAB 42.87
- Support Level
- NCA $8.42
- YMAB $4.02
- Resistance Level
- NCA $8.58
- YMAB $4.60
- Average True Range (ATR)
- NCA 0.09
- YMAB 0.32
- MACD
- NCA 0.03
- YMAB -0.01
- Stochastic Oscillator
- NCA 100.00
- YMAB 23.93
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.